Fucoidan Inhibits Lymphangiogenesis by Downregulating the Expression of VEGFR3 and PROX1 in Human Lymphatic Endothelial Cells

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 May 21

PMID 27203545

Citations 13

Authors

Yazong Yang

Zixiang Gao

Yanhong Ma

Hongming Teng

Zundong Liu

Hengyun Wei

Yanbing Lu

Xiaofang Cheng

Lin Hou

Xiangyang Zou

Affiliations

Soon will be listed here.

Abstract

Lymphangiogenesis is one of the promoters of tumor lymphatic metastasis. Fucoidan which is a fucose-enriched sulfated polysaccharide has effect on various pharmacological activities including anti-metastasis activity. However, the inhibitory effect of fucoidan on lymphangiogenesis remains unclear. Here, fucoidan extracted from U. pinnatifida sporophylls suppressed HLECs proliferation, migration and tube-like structure formation, and had inhibitory effect of tumor-induced lymphangiogenesis in vitro. Additionally, we found that fucoidan had a dose-dependent depressive effect on the expressions of PROX1, vascular endothelial growth factor receptor 3 (VEGFR3), NF-κB, phospho-PI3K and phospho-Akt in HLECs. Moreover, anti-lymphangiogenesis effect of fucoidan was assessed by using mouse tumor model. In summary, fucoidan inhibit tumor lymphangiogenesis and lymphatic metastasis by suppressing the NF-κB/PI3K/Akt signaling pathway through reduced levels of PROX1 and VEGFR3.

Citing Articles

ZNF468-mediated epigenetic upregulation of VEGF-C facilitates lymphangiogenesis and lymphatic metastasis in ESCC via PI3K/Akt and ERK1/2 signaling pathways.

Zhu J, Qiu X, Jin X, Nie X, Ou S, Wu G Cell Oncol (Dordr). 2024; 47(5):1927-1942.

PMID: 39141315 DOI: 10.1007/s13402-024-00976-0.

Ten Years of Research on Fucoidan and Cancer: Focus on Its Antiangiogenic and Antimetastatic Effects.

Turrini E, Maffei F, Fimognari C Mar Drugs. 2023; 21(5).

PMID: 37233501 PMC: 10223425. DOI: 10.3390/md21050307.

Advances in Drugs Targeting Lymphangiogenesis for Preventing Tumor Progression and Metastasis.

Wang C, Chu M Front Oncol. 2022; 11:783309.

PMID: 35087755 PMC: 8787832. DOI: 10.3389/fonc.2021.783309.

Low molecular weight fucoidan inhibits hepatocarcinogenesis and nonalcoholic fatty liver disease in zebrafish via ASGR/STAT3/HNF4A signaling.

Wu S, Yang W, Cheng C, Lin K, Sampurna B, Chan S Clin Transl Med. 2020; 10(8):e252.

PMID: 33377648 PMC: 7752165. DOI: 10.1002/ctm2.252.

Low Molecular Weight Fucoidan Prevents Radiation-Induced Fibrosis and Secondary Tumors in a Zebrafish Model.

Wu S, Yang W, Cheng C, Hsiao M, Tsai S, Lin H Cancers (Basel). 2020; 12(6).

PMID: 32570707 PMC: 7353073. DOI: 10.3390/cancers12061608.

References

Chen M, Hsu W, Hwang P, Chou T . Low Molecular Weight Fucoidan Inhibits Tumor Angiogenesis through Downregulation of HIF-1/VEGF Signaling under Hypoxia. Mar Drugs. 2015; 13(7):4436-51. PMC: 4515626. DOI: 10.3390/md13074436. View

Saharinen P, Tammela T, Karkkainen M, Alitalo K . Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 2004; 25(7):387-95. DOI: 10.1016/j.it.2004.05.003. View

Flister M, Wilber A, Hall K, Iwata C, Miyazono K, Nisato R . Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1. Blood. 2009; 115(2):418-29. PMC: 2808162. DOI: 10.1182/blood-2008-12-196840. View

Atashrazm F, Lowenthal R, Woods G, Holloway A, Dickinson J . Fucoidan and cancer: a multifunctional molecule with anti-tumor potential. Mar Drugs. 2015; 13(4):2327-46. PMC: 4413214. DOI: 10.3390/md13042327. View

Molinsky J, Klanova M, Maswabi B, Soukup T, Trneny M, Necas E . In vivo growth of mantle cell lymphoma xenografts in immunodeficient mice is positively regulated by VEGF and associated with significant up-regulation of CD31/PECAM1. Folia Biol (Praha). 2013; 59(1):26-31. View

Li S, Li Q . Cancer stem cells, lymphangiogenesis, and lymphatic metastasis. Cancer Lett. 2014; 357(2):438-47. DOI: 10.1016/j.canlet.2014.12.013. View

Chen J, Chang Y, Hong C, Yu Y, Su J . The role of the VEGF-C/VEGFRs axis in tumor progression and therapy. Int J Mol Sci. 2013; 14(1):88-107. PMC: 3565253. DOI: 10.3390/ijms14010088. View

Wilting J, Papoutsi M, Christ B, Nicolaides K, von Kaisenberg C, Borges J . The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues. FASEB J. 2002; 16(10):1271-3. DOI: 10.1096/fj.01-1010fje. View

Ou J, Wei X, Peng Y, Zha L, Zhou R, Shi H . Neuropilin-2 mediates lymphangiogenesis of colorectal carcinoma via a VEGFC/VEGFR3 independent signaling. Cancer Lett. 2014; 358(2):200-209. DOI: 10.1016/j.canlet.2014.12.046. View

10.

Teng H, Yang Y, Wei H, Liu Z, Liu Z, Ma Y . Fucoidan Suppresses Hypoxia-Induced Lymphangiogenesis and Lymphatic Metastasis in Mouse Hepatocarcinoma. Mar Drugs. 2015; 13(6):3514-30. PMC: 4483642. DOI: 10.3390/md13063514. View

11.

Zhang Z, Sun J, Hao L, Liu C, Ma H, Jia L . Modification of glycosylation mediates the invasive properties of murine hepatocarcinoma cell lines to lymph nodes. PLoS One. 2013; 8(6):e65218. PMC: 3688732. DOI: 10.1371/journal.pone.0065218. View

12.

Srinivasan R, Escobedo N, Yang Y, Interiano A, Dillard M, Finkelstein D . The Prox1-Vegfr3 feedback loop maintains the identity and the number of lymphatic endothelial cell progenitors. Genes Dev. 2014; 28(19):2175-87. PMC: 4180978. DOI: 10.1101/gad.216226.113. View

13.

Gomes F, Nedel F, Alves A, Nor J, Tarquinio S . Tumor angiogenesis and lymphangiogenesis: tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms. Life Sci. 2012; 92(2):101-7. PMC: 3740377. DOI: 10.1016/j.lfs.2012.10.008. View

14.

Cross M, Dixelius J, Matsumoto T, Claesson-Welsh L . VEGF-receptor signal transduction. Trends Biochem Sci. 2003; 28(9):488-94. DOI: 10.1016/S0968-0004(03)00193-2. View

15.

Hong Y, Detmar M . Prox1, master regulator of the lymphatic vasculature phenotype. Cell Tissue Res. 2003; 314(1):85-92. DOI: 10.1007/s00441-003-0747-8. View

16.

Liu F, Wang J, Chang A, Liu B, Yang L, Li Q . Fucoidan extract derived from Undaria pinnatifida inhibits angiogenesis by human umbilical vein endothelial cells. Phytomedicine. 2012; 19(8-9):797-803. DOI: 10.1016/j.phymed.2012.03.015. View

17.

Chen H, Guan R, Lei Y, Chen J, Ge Q, Zhang X . Lymphangiogenesis in gastric cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis. BMC Cancer. 2015; 15:103. PMC: 4358729. DOI: 10.1186/s12885-015-1109-0. View

18.

Mumprecht V, Detmar M . Lymphangiogenesis and cancer metastasis. J Cell Mol Med. 2009; 13(8A):1405-16. PMC: 3572232. DOI: 10.1111/j.1582-4934.2009.00834.x. View

19.

Dieterich L, Detmar M . Tumor lymphangiogenesis and new drug development. Adv Drug Deliv Rev. 2015; 99(Pt B):148-160. DOI: 10.1016/j.addr.2015.12.011. View

20.

Deng Y, Simons M . Lymphatic fate determination: playing RAF with ERK. Cell Cycle. 2013; 12(8):1157-8. PMC: 3674076. DOI: 10.4161/cc.24491. View